Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 4/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.34 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
| ▸ | PNP | P00491 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 2/20 | 0.30 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13384043 | 0.84 | DOT1L (0.33) | — | |
| SCHEMBL13384046 | 0.80 | — | — | |
| SCHEMBL13384048 | 0.79 | P2RY2 (0.43) | — | |
| SCHEMBL6243042 | 0.78 | HINT1 (0.50) | HINT1TAS1R3TAS1R1HPGDNT5E | |
| SCHEMBL6242507 | 0.76 | HINT1 (0.50) | HINT1TAS1R3TAS1R1NT5EKRAS | |
| SCHEMBL25680113 | 0.76 | KDM4E (0.47) | HINT1IMPDH2IMPDH1TAS1R3TAS1R1 | |
| SCHEMBL20248707 | 0.76 | KDM4E (0.47) | HINT1IMPDH2IMPDH1TAS1R3TAS1R1 | |
| SCHEMBL14896399 | 0.76 | HINT1 (0.49) | HINT1TAS1R3TAS1R1HPGDNT5E | |
| SCHEMBL27104282 | 0.76 | KDM4E (0.51) | HINT1IMPDH2IMPDH1TAS1R3TAS1R1 | |
| SCHEMBL17589239 | 0.76 | KDM4E (0.37) | HINT1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087634-A1 | Fluorous Oligonucleotide Reagents and Affinity Purification of Oligonucleotides | BERRY & ASSOCIATES, INC. (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087634-A1 | Fluorous Oligonucleotide Reagents and Affinity Purification of Oligonucleotides | DCLRE1B, POLM, FBL | HINT1 2874/4885IMPDH2 2798/4885IMPDH1 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.